메뉴 건너뛰기




Volumn 34, Issue 8, 2016, Pages 741-750

Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal—An Evidence Review Group Perspective

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON ALPHA; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

EID: 84958747393     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-016-0387-y     Document Type: Review
Times cited : (10)

References (13)
  • 1
    • 84982944216 scopus 로고    scopus 로고
    • National Institute for Health and Clinical Excellence (NICE) Guide to the methods of technology appraisal. London, NICE 2013 2008
    • National Institute for Health and Clinical Excellence (NICE) Guide to the methods of technology appraisal. London, NICE 2013 Available at: http://www.nice.org.uk/. 2008.
  • 2
    • 84982944219 scopus 로고    scopus 로고
    • Gilead Sciences Inc. Manufacturer/sponsor submission of evidence for Single Technology Appraisal (STA) of ledipasvir-sofosbuvir for treating chronic hepatitis C [ID742]—Company submission. 2014
    • Gilead Sciences Inc. Manufacturer/sponsor submission of evidence for Single Technology Appraisal (STA) of ledipasvir-sofosbuvir for treating chronic hepatitis C [ID742]—Company submission. 2014.
  • 4
    • 84983019548 scopus 로고    scopus 로고
    • National Institute for Health and Care Excellence, Single Technology Appraisal (STA): ledipasvir-sofosbuvir for treating chronic hepatitis C [ID742]. 2015
    • National Institute for Health and Care Excellence, Single Technology Appraisal (STA): ledipasvir-sofosbuvir for treating chronic hepatitis C [ID742]. 2015.
  • 5
    • 84983004999 scopus 로고    scopus 로고
    • European Public Assessment Report—Harvoni
    • European Medicine Agency. European Public Assessment Report—Harvoni. London: EMA; 2014.
    • (2014) London: EMA
  • 6
    • 84982877763 scopus 로고    scopus 로고
    • National Institute for Health and Care Excellence, Final appraisal determination ledipasvir-sofosbuvir for treating chronic hepatitis C [ID742]. 2015
    • National Institute for Health and Care Excellence, Final appraisal determination ledipasvir-sofosbuvir for treating chronic hepatitis C [ID742]. 2015.
  • 7
    • 84900339263 scopus 로고    scopus 로고
    • Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
    • PID: 24725239
    • Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–98.
    • (2014) N Engl J Med , vol.370 , Issue.20 , pp. 1889-1898
    • Afdhal, N.1    Zeuzem, S.2    Kwo, P.3    Chojkier, M.4    Gitlin, N.5    Puoti, M.6
  • 8
    • 84898669547 scopus 로고    scopus 로고
    • Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
    • COI: 1:CAS:528:DC%2BC2cXmvFShtLk%3D, PID: 24725238
    • Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483–93.
    • (2014) N Engl J Med , vol.370 , Issue.16 , pp. 1483-1493
    • Afdhal, N.1    Reddy, K.R.2    Nelson, D.R.3    Lawitz, E.4    Gordon, S.C.5    Schiff, E.6
  • 9
    • 84900326091 scopus 로고    scopus 로고
    • Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
    • PID: 24720702
    • Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–88.
    • (2014) N Engl J Med , vol.370 , Issue.20 , pp. 1879-1888
    • Kowdley, K.V.1    Gordon, S.C.2    Reddy, K.R.3    Rossaro, L.4    Bernstein, D.E.5    Lawitz, E.6
  • 10
    • 77950597305 scopus 로고    scopus 로고
    • Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin
    • COI: 1:CAS:528:DC%2BC3cXls1Cnt7c%3D, PID: 20069649
    • Martinot-Peignoux M, Stern C, Maylin S, Ripault MP, Boyer N, Leclere L, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology. 2010;51(4):1122–6.
    • (2010) Hepatology , vol.51 , Issue.4 , pp. 1122-1126
    • Martinot-Peignoux, M.1    Stern, C.2    Maylin, S.3    Ripault, M.P.4    Boyer, N.5    Leclere, L.6
  • 11
    • 84877782905 scopus 로고    scopus 로고
    • Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies
    • PID: 23470616
    • Chen J, Florian J, Carter W, Fleischer RD, Hammerstrom TS, Jadhav PR, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology. 2013;144(7):1450–5.
    • (2013) Gastroenterology , vol.144 , Issue.7 , pp. 1450-1455
    • Chen, J.1    Florian, J.2    Carter, W.3    Fleischer, R.D.4    Hammerstrom, T.S.5    Jadhav, P.R.6
  • 12
    • 84982896237 scopus 로고    scopus 로고
    • Hepatitis C (chronic)—sofosbuvir: consultation document. ID654
    • National Instiute for Health and Care Excellence. Hepatitis C (chronic)—sofosbuvir: consultation document. ID654. London: NICE; 2014.
    • (2014) London: NICE
  • 13
    • 33746633881 scopus 로고    scopus 로고
    • Wright M, Grieve R, Roberts J, Main J, Thomas HC. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess. 2006; 10(21):1–113, iii
    • Wright M, Grieve R, Roberts J, Main J, Thomas HC. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess. 2006; 10(21):1–113, iii.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.